Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Current influenza vaccines stimulate neutralising antibody to the haemagglutinin antigen but as there is antigenic drift in HA it is difficult to prepare a vaccine in advance against an emergent strain. A potential strategy is to induce CD8(+) and CD4(+) T cells that recognize epitopes within internal proteins that are less subject to antigenic drift. Augmenting humoral responses to HA with T cell responses to more conserved antigens may result in a more broadly protective vaccine. In this study, we evaluate the quality of influenza specific T cell responses in a clinical trial using MVA-NP+M1 vaccination followed by influenza virus challenge. In vaccinated volunteers, the expression of Granzyme A, Perforin and CD57 on influenza HLA A*02 M158-66 antigen specific cells was higher than non-vaccinated volunteers before and after challenge despite a similar frequency of antigen specific cells. BCL2 expression was lower in vaccinated volunteers. These data indicate that antigen specific T cells are a useful additional measure for use in human vaccination or immunization studies.

Original publication

DOI

10.1371/journal.pone.0062778

Type

Journal article

Journal

PLoS One

Publication Date

2013

Volume

8

Keywords

Adolescent, Adult, Antigens, Viral, CD57 Antigens, CD8-Positive T-Lymphocytes, Epitopes, T-Lymphocyte, Granzymes, HLA-A2 Antigen, Hemagglutinins, Humans, Influenza Vaccines, Influenza, Human, Middle Aged, Nucleoproteins, Orthomyxoviridae, Perforin, Recombinant Proteins, Vaccination, Vaccines, Synthetic, Viral Core Proteins, Viral Matrix Proteins, Viral Vaccines